Robuta

https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/azd1222-us-phase-iii-trial-met-primary-efficacy--endpoint-in-pre.html AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis phase iii trial primary efficacy endpoint interim analysis met preventing